Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02774681 · ClinicalTrials.gov registry record · Phase 2
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02774681 is a Phase 2 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 12 participants.
The verdict
NCT02774681, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain and also to determine the overall radiographic response rate in the CNS. Palbociclib is an anti-cancer medication that has been shown to stop cancer cells from growing. It has been approved in hormone positive breast cancer, along with other hormone therapies and has been found to be effective. The preclinical studies suggest that the drug may also have activity in other types of breast cancer, such as HER2 positive breast cancer. The purpose of this study is to see if the study drug is effective in patients with brain metastasis, who have HER2-positive breast cancer.
Interventions
- DRUG Palbociclib
- PROCEDURE Cognitive Assessment
- BIOLOGICAL Trastuzumab
- PROCEDURE Quality-of-Life Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-08-31 |
| Est. Completion | 2020-02-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02774681
The ClinicalTrials.gov registry entry for NCT02774681 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Palbociclib is the first listed.
NCT02774681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02774681 about?
NCT02774681 is a clinical study titled "Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis". The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain and also to determine the overall radiographic response rate in the CNS. Palbociclib is an anti-cancer medication that has been shown to stop cancer c...
What is the current status of trial NCT02774681?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2016-08-31. Estimated completion is 2020-02-16.
What interventions are being tested in trial NCT02774681?
The interventions under investigation include: Palbociclib (DRUG), Cognitive Assessment (PROCEDURE), Trastuzumab (BIOLOGICAL), Quality-of-Life Assessment (PROCEDURE).
Who is sponsoring clinical trial NCT02774681?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.